ABC transporters in CSCs membranes as a novel target for treating tumor relapse

Frontiers in Pharmacology

Volumn 5 JUL, Issue , 2014, Pages

  Zinzi, Laura ^a   Contino, Marialessandra ^a   Cantore, Mariangela ^a   Capparelli, Elena ^a   Leopoldo, Marcello ^a   Colabufo, Nicola A ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

CSCs; HTS; MDR; P gp; TICs markers

Indexed keywords

ABC TRANSPORTER; ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE ISOENZYME 1; APAZIQUONE; BANOXANTRONE; CARBOPLATIN; CD133 ANTIGEN; CD24 ANTIGEN; CISPLATIN; DACTINOMYCIN; DISULFIRAM; DOCETAXEL; DOXORUBICIN; HERMES ANTIGEN; MEPACRINE; METFORMIN; MITHRAMYCIN; N,N' BIS(2 BROMOETHYL)PHOSPHORODIAMIDIC ACID (1 METHYL 2 NITRO 1H IMIDAZOL 5 YL)METHYL ESTER; NICLOSAMIDE; NOTCH RECEPTOR; PACLITAXEL; PRODRUG; SALINOMYCIN; STEM CELL FACTOR RECEPTOR; TIRAPAZAMINE; TRASTUZUMAB; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE;

ALCOHOLISM; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STEM CELL; CELL ISOLATION; DRUG CYTOTOXICITY; DRUG STRUCTURE; DRUG TARGETING; HEDGEHOG PATHWAY; HIGH THROUGHPUT SCREENING; HUMAN; MULTIDRUG RESISTANCE; NEPHROBLASTOMA; NONHUMAN; NOTCH PATHWAY; PHOTOCHEMICAL INTERNALIZATION; PI3K AKT PATHWAY; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; TESTIS CANCER; TROPHOBLASTIC TUMOR; TUMOR MICROENVIRONMENT; TUMOR RECURRENCE; WNT SIGNALING PATHWAY;

EID: 84904764840     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2014.00163     Document Type: Review

References (180)

1. Abdul-Ghani, R., Serra, V., Györffy, B., Jürchott, K., Solf, A., and Schäfer, R. (2006). The PI3K inhibitor LY294002 blocks drug export from resistant colon carcinoma cells overexpressing MRP1. Oncogene 25, 1743-1752. doi: 10.1038/sj.onc.1209201
2. Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., and Clarke, M. F. (2003). Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 100, 3983-3988. doi: 10.1073/pnas.0530291100
3. Alvero, A. B., Montagna, M. K., Holmberg, J. C., Craveiro, V., Brown, D., and Mor, G. (2011). Targeting the mitochondria activates two independent cell death pathways in ovarian cancer stem cells. Mol. Cancer Ther. 10, 1385-1393. doi: 10.1158/1535-7163.MCT-11-0023
4. An, Y., and Ongkeko, W. M. (2009). ABCG2: the key to chemoresistance in cancer stem cells? Expert Opin. Drug Metab. Toxicol. 5, 1529-1542. doi: 10.1517/17425250903228834
5. Baccelli, I., and Trumpp, A. (2012). The evolving concept of cancer and metastasis stem cells. J. Cell Biol. 198, 281-293. doi: 10.1083/jcb.201202014
6. Bar, E. E., Chaudhry, A., Lin, A., Fan, X., Schreck, K., Matsui, W., et al. (2007). Cyclopamine-mediated Hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells 25, 2524-2533. doi: 10.1634/stemcells.2007-0166
7. Barancík, M., Bohácová, V., Sedlák, J., Sulová, Z., and Breier, A. (2006). LY294,002, a specific inhibitor of PI3K/Akt kinase pathway, antagonizes P-glycoprotein mediated multidrug resistance. Eur. J. Pharm. Sci. 29, 426-434. doi: 10.1016/j.ejps.2006.08.006
8. Basu, D., Montone, K. T., Wang, L. P., Gimotty, P. A., Hammond, R., Diehl, J. A., et al. (2011). Detecting and targeting mesenchymal-like subpopulations within squamous cell carcinomas. Cell Cycle 10, 12008-12016. doi: 10.4161/cc.10.12.15883
9. Blaumueller, C. M., Qi, H., Zagouras, P., and Artavanis-Tsakonas, S. (1997). Intracellular cleavage of Notch leads to a heterodimic receptor on plasma membrane. Cell 90, 281-291. doi: 10.1016/S0092-8674(00)80336-0
10. Bleau, A. M., Hambardzumyan, D., Ozawa, T., Fomchenko, E. I., Huse, J. T., Brennan, C. W., et al. (2009). PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cell. Cell Stem Cell 4, 226-235. doi: 10.1016/j.stem.2009.01.007
11. Bokesch, H. R., Gardella, R. S., Rabe, D. C., Bottaro, D. P., Linehan, W. M., McMahon, J. B., et al. (2011). A new hypoxia inducible factor-2 inhibitory pyrrolinone alkaloid from roots and stems of Piper sarmentosum. Chem. Pharm. Bull. 59, 1178-1179. doi: 10.1248/cpb.59.1178
12. Boman, B. M., and Wicha, M. S. (2008). Cancer stem cells: a step toward the cure. J. Clin. Oncol. 26, 2795-2799. doi: 10.1200/JCO.2008.17.7436
13. Bostad, M., Berg, K., Høgset, A., Skarpen, E., Stenmark, H., and Selbo, P. K. (2013). Photochemical internalization (PCI) of immunotoxins targeting CD133 is specific and highly potent at femtomolar levels in cells with cancer stemcell properties. J. Control. Release 168, 317-326. doi: 10.1016/j.jconrel.2013.03.023
14. Brou, C., Loget, F., Gupta, N., Bessia, C., LeBail, O., Doedens, J. R., et al. (2000). A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE. Mol. Cell 5, 207-216. doi: 10.1016/S1097-2765(00)80417-7
15. Cabarcas, S. M., Mathews, L. A., and Farrar, W. L. (2011). The cancer stem cell niche-there goes the neighborhood? Int. J. Cancer 129, 2315-2327. doi: 10.1002/ijc.26312
16. Calcagno, A. M., Salcido, C. D., Gillet, J. P., Wu, C. P., Fostel, J. M., Mumau, M. D., et al. (2010). Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics. J. Natl. Cancer Inst. 102, 1637-1652. doi: 10.1093/jnci/djq361
17. Cao, Z., Tong, R., Mishra, A., Xu, W., Whong, G. C., Cheng, J., et al. (2009). Reversible cell-specific drug delivery with aptamer-funcionalized liposomes. Angew. Chem. Int. Ed. Engl. 48, 6494-6498. doi: 10.1002/anie.200901452
18. Carla, F., Kim, B., Jackson, E. L., Woolfenden, A. E., Lawrence, S., Babar, I., et al. (2005). Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 121, 823-835. doi: 10.1016/j.cell.2005.03.032
19. Challen, G. A., and Little, M. H. (2006). A side order of stem cells: the SP phenotype. Stem Cells 24, 3-12. doi: 10.1634/stemcells.2005-0116
20. Charafe-Jauffret, E., Ginestier, C., Iovino, F., Tarpin, C., Diebel, M., Esterni, B., et al. (2010). Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin. Cancer Res. 16, 45-55. doi: 10.1158/1078-0432.CCR-09-1630
21. Chen, B., Dodge, M. E., Tang, W., Lu, J., Ma, Z., Fan, C. W., et al. (2009). Small moleculemediated disruption of Wnt dependent signaling in tissue regeneration and cancer. Nat. Chem. Biol. 5, 100-107. doi: 10.1038/nchembio.137
22. Cheung, A. M., Wan, T. S., Leung, J. C., Chan, L. Y., Huang, H., Kwong, Y. L., et al. (2007). Aldehyde dehydrogenase activity in leukemic blasts defines a subgroup of acute myeloid leukemia with adverse prognosis and superior NOD/SCID engrafting potential. Leukemia 21, 1423-1430. doi: 10.1038/sj.leu.2404721
23. Clevers, H. (2011). The cancer stem cell: premises, promises and challenges. Nat. Med. 17, 313-319. doi: 10.1038/nm.2304
24. Clevers, H., and Nusse, R. (2012). Wnt/beta-catenin signaling and disease. Cell 149, 1192-1205. doi: 10.1016/j.cell.2012.05.012
25. Colabufo, N. A., Berardi, F., Cantore, M., Contino, M., Inglese, C., Niso, M., et al. (2010). Perspectives of P-glycoprotein modulating agents in oncology and neurodegenerative diseases: pharmaceutical, biological, and diagnostic potentials. J. Med. Chem. 53, 1883-1897. doi: 10.1021/jm900743c
26. Colabufo, N. A., Berardi, F., Cantore, M., Perrone, M. G., Contino, M., Inglese, C., et al. (2008a). Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives. Bioorg. Med. Chem. 16, 362-373. doi: 10.1016/j.bmc.2007.09.039
27. Colabufo, N. A., Berardi, F., Cantore, M., Perrone, M. G., Contino, M., Inglese, C., et al. (2008b). 4-Biphenyl and 2-naphthyl substituted 6,7-dimethoxytetrahydroisoquinoline derivatives as potent P-gp modulators. Bioorg. Med. Chem. 16, 3732-3743. doi: 10.1016/j.bmc.2008.01.055
28. Colabufo, N. A., Berardi, F., Cantore, M., Perrone, M. G., Contino, M., Inglese, C., et al. (2009). Multi-drug-resistance-reverting agents: 2-aryloxazole and 2-arylthiazole derivatives as potent BCRP or MRP1 inhibitors. ChemMedChem 4, 188-195. doi: 10.1002/cmdc.200800329
29. Colabufo, N. A., Berardi, F., Contino, M., Inglese, C., and Perrone, R. (2008c). Multidrug Resistance: Biological and Pharmaceutical Advance in the Antitumour Treatment. Kerala: Research Signpost.
30. Colabufo, N. A., Contino, M., Cantore, M., Capparelli, E., Perrone, M. G., Cassano, G., et al. (2013). Naphthalenyl derivatives for hitting P-gp/MRP1/BCRP transporters. Bioorg. Med. Chem. 21, 1322-1330. doi: 10.1016/j.bmc.2012.12.021
31. Coley, H. M. (2010). Overcoming multidrug resistance in cancer: clinical studies of p-glycoprotein inhibitors. Methods Mol. Biol. 596, 341-358. doi: 10.1007/978-1-60761-416-6_15
32. Contino, M., Cantore, M., Capparelli, E., Perrone, M. G., Niso, M., Inglese, C., et al. (2012). A benzopyrane derivative as P-glycoprotein stimulator: a potential agent to decrease ß-amyloid accumulation in Alzheimer's disease. ChemMedChem 7, 391-395. doi: 10.1002/cmdc.201100469
33. Contino, M., Zinzi, L., Cantore, M., Perrone, M. G., Leopoldo, M., Berardi, F., et al. (2013b). Activity-Lipophilicity relationship studies on P-gp ligands designed as simplified Tariquidar bulky fragments. Bioorg. Med. Chem. Lett. 23, 3728-3731. doi: 10.1016/j.bmcl.2013.05.019
34. Contino, M., Zinzi, L., Perrone, M. G., Leopoldo, M., Berardi, F., Perrone, R., et al. (2013a). Potent and selective tariquidar bioisosters as potential PET radiotracers for imaging P-gp. Bioorg. Med. Chem. Lett. 23, 1369-1373. doi: 10.1016/j.bmcl.2012.12.084
35. Dean, M., Fojo, T., and Bates, S. (2005). Tumour stem cells and drug resistance. Nat. Rev. Cancer 5, 275-284. doi: 10.1038/nrc1590
36. Dobbin, Z. C., and Landen, C. N. (2013). Isolation and characterization of potential cancer stem cells from solid human tumors-potential applications. Curr. Protoc. Pharmacol. 63, Unit 14.28. doi: 10.1002/0471141755.ph1428s63
37. Dong, T. T., Zhou, H. M., Wang, L. L., Feng, B., Lv, B., and Zheng, M. H. (2011). Salinomycin selectively targets'CD133+' cell subpopulations and decreases malignant traits in colorectal cancer lines. Ann. Surg. Oncol. 18, 6797-1804. doi: 10.1245/s10434-011-1561-2
38. Dubrovska, A., Kim, S., Salamone, R. J., Walker, J. R., Maira, S. M., García-Echeverría, C., et al. (2009). The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc. Natl. Acad. Sci. U.S.A. 106, 268-273. doi: 10.1073/pnas.0810956106
39. Ellington, A. D., and Szostak, J. W. (1990). In vitro selection of RNA molecules that bind specific ligands. Nature 346, 818-822. doi: 10.1038/346818a0
40. Erba, E., Ubezio, P., Broggini, M., Ponti, M., and D'Incalci, M. (1988). DNA damage, cytotoxic effect and cell-cycle perturbation of Hoechst 33342 on L1210 cells in vitro. Cytometry 9, 1-6. doi: 10.1002/cyto.990090102
41. Fael Al-Mayhani, T. M., Ball, S. L., Zhao, J. W., Fawcett, J., Ichimura, K., Collins, P. V., et al. (2009). An efficient method for derivation and propagation of glioblastoma cell lines that conserves the molecular profile of their original tumours. J. Neurosci. Methods 176, 192-199. doi: 10.1016/j.jneumeth.2008.07.022
42. Fang, D., Nguyen, T. K., Leishear, K., Finko, R., Kulp, A. N., Hotz, S., et al. (2005). A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res. 65, 9328-9337. doi: 10.1158/0008-5472.CAN-05-1343
43. Farokhzad, O. C., Cheng, J., Teply, B. A., Sherifi, I., Jon, S., Kantoff, P. W., et al. (2006). Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc. Natl. Acad. Sci. U.S.A. 103, 6315-6320. doi: 10.1073/pnas.0601755103
44. Feldmann, G., Dhara, S., Fendrich, V., Bedja, D., Beaty, R., Mullendore, M., et al. (2007). Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res. 67, 2187-2196. doi: 10.1158/0008-5472.CAN-06-3281
45. Feldmann, H. J. (2001). Oxygenation of human tumors-implications for combined therapy. Lung Cancer 33, S77-S83. doi: 10.1016/S0169-5002(01)00306-3
46. Feng, X., Zhou, Q., Liu, C., and Tao, M. (2012). Drug screening study using glioma stem-like cells. Mol. Med. Rep. 6, 1117-1120. doi: 10.3892/mmr.2012.1040
47. Foehrenbacher, A., Patel, K., Abbattista, M., Guise, C. P., Secomb, T. W., Wilson, W. R., et al. (2013). The role of by stander effects in the antitumor activity of the hypoxia-activated prodrug PR-104. Front. Oncol. 3:263. doi: 10.3389/fonc.2013.00263
48. Fraschini, A., Bottone, M. G., Scovassi, A. I., Denegri, M., Risueño, M. C., Testillano, P. S., et al. (2005). Changes in extranucleolar transcription during actinomycin D-induced apoptosis. Histol. Histopathol. 20, 107-117.
49. Frei, E. 3rd. (1974). The clinical use of actinomycin. Cancer Chemother. Rep. 58, 49-54.
50. Fuchs, D., Daniel, V., Sadeghi, M., Opelz, G., and Naujokat, C. (2010). Salinomycin overcomes ABC transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like KG-1a cells. Biochem. Biophys. Res. Commun. 394, 1098-1104. doi: 10.1016/j.bbrc.2010.03.138
51. Gao, M. Q., Choi, Y. P., Kang, S., Youn, J. H., and Cho, N. H. (2010). CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene 29, 2672-2680. doi: 10.1038/onc.2010.35
52. Geiger, A., Burgstaller, P., von der Eltz, H., Roeder, A., and Famulok, M. (1996). RNA aptamers that bind L-arginine with sub-micromolar dissociation constants and high enantioselectivity. Nucleic Acids Res. 24, 1029-1036. doi: 10.1093/nar/24.6.1029
53. Germain, A. R., Carmody, L. C., Nag, P. P., Morgan, B., VerPlank, L., Fernandez, C., et al. (2013). Cinnameds as selectiva small-molecule inhibitors of a cellular model of breast cancer stem cells. Bioorg. Med. Chem. Lett. 23, 1834-1838. doi: 10.1016/j.bmcl.2013.01.025
54. Gimenez-Bonafe, P., Guillen Canovas, A., Ambrosio, S., Tortosa, A., and Perez-Tomas, R. (2008). "Drugs modulating MDR," in Multidrug Resistance: Biological and Pharmaceutical Advance in the Antitumour Treatment, ed N. A. Colabufo (Kerala: Research Signpost), 63-99.
55. Goodell, M. A., Brose, K., Paradis, G., Conner, A. S., and Mulligan, R. C. (1996). Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J. Exp. Med. 183, 1797-1806. doi: 10.1084/jem.183.4.1797
56. Gotlieb, W. H., Saumet, J., Beauchamp, M. C., Gu, J., Lau, S., Pollak, M. N., et al. (2008). In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol. Oncol. 110, 246-250. doi: 10.1016/j.ygyno.2008.04.008
57. Griguer, C. E., Oliva, C. R., Gobin, E., Marcorelles, P., Benos, D. J., Lancaster, J. R. Jr., et al. (2008). CD133 is a marker of bioenergetic stress in human glioma. PLoS ONE 3:e3655. doi: 10.1371/journal.pone.0003655
58. Guise, C. P., Mowday, A. M., Ashoorzadeh, A., Yuan, R., Lin, W. H., Wu, D. H., et al. (2014). Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia. Chin. J. Cancer 33, 80-86. doi: 10.5732/cjc.012.10285
59. Gupta, S. C., Sundaram, C., Reuter, S., and Aggarwal, B. B. (2010). Inhibiting NF-?B activation by small molecules as a therapeutic strategy. Biochim. Biophys. Acta 1799, 775-787. doi: 10.1016/j.bbagrm.2010.05.004
60. Hambardzumyan, D., Becher, O. J., Rosenblum, M. K., Pandolfi, P. P., Manova-Todorova, K., and Holland, E. C. (2008). PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes Dev. 22, 436-448. doi: 10.1101/gad.1627008
61. Hamburger, A. W., and Salmon, S. E. (1977). Primary bioassay of human tumor stem cells. Science 197, 461-463. doi: 10.1126/science.560061
62. Hanahan, D., and Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell 144, 646-674. doi: 10.1016/j.cell.2011.02.013
63. Hemmati, H. D., Nakano, I., Lazareff, J. A., Masterman-Smith, M., Geschwind, D. H., Bronner-Fraser, M., et al. (2003). Cancerous stem cells can arise from pediatric brain tumors. Proc. Natl. Acad. Sci. U.S.A. 100, 15178-15183. doi: 10.1073/pnas.2036535100
64. Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y., and Mills, G. B. (2005). Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. 4, 988-1004. doi: 10.1038/nrd1902
65. Hicks, K. O., Siim, B. G., Jaiswal, J. K., Pruijn, F. B., Fraser, A. M., Patel, R., et al. (2010). Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors. Clin. Cancer Res. 16, 20946-20957. doi: 10.1158/1078-0432.CCR-10-1439
66. Hirsch, H. A., Iliopoulos, D., Tsichlis, P. N., and Struhl, K. (2009). Metformin selectively targets cancer stem cells, and acts togheter with chemotherapy in block tumor growth and prolong remission. Cancer Res. 69, 7507-7511. doi: 10.1158/0008-5472.CAN-09-2994
67. Hirschhaeuser, F., Menne, H., Dittfeld, C., West, J., Mueller-Klieser, W., and Kunz-Schughart, L. A. (2010). Multicellular tumor spheroids: an underestimated tool is catching up again. J. Biotechnol. 148, 3-15. doi: 10.1016/j.jbiotec.2010.01.012
68. Holohan, C., Van Schaeybroeck, S., Longley, D. B., and Johnston, P. G. (2013). Cancer drug resistance: an evolving paradigm. Nat. Rev. Cancer 13, 714-726. doi: 10.1038/nrc3599
69. Hothi, P., Martins, T. J., Chen, L., Deleyrole, L., Yoon, J.-G., Reynolds, B., et al. (2012). High-throughput chemical screens identify Disulfiram as an inhibitor of human glioblastoma stem cells. Oncotarget 3, 1124-1136.
70. Huang, E. H., Hynes, M. J., Zhang, T., Ginestier, C., Dontu, G., Appelman, H., et al. (2009a). Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res. 69, 3382-3389. doi: 10.1158/0008-5472.CAN-08-4418
71. Huang, S. M., Mishina, Y. M., Liu, S., Cheung, A., Stegmeier, F., Michaud, G. A., et al. (2009b). Tankyrase inhibition stabilizes axin and antagonizes Wnt signaling. Nature 461, 614-620. doi: 10.1038/nature08356
72. Imai, Y., Yamagishi, H., Ono, Y., and Ueda, Y. (2012). Versatile inhibitory effects of the flavonoid-derived PI3K/Akt inhibitor, LY294002, on ATP-binding cassette transporters that characterize stem cells. Clin. Transl. Med. 1, 24-28. doi: 10.1186/2001-1326-1-24
73. Iyer, U., and Kadambi, V. J. (2011). Antibody drug conjugates-Trojan horses in the war on cancer. J. Pharmacol. Toxicol. Methods 64, 207-212. doi: 10.1016/j.vascn.2011.07.005
74. James, R. G., Davidson, K. C., Bosch, K. A., Biechele, T. L., Robin, N. C., Taylor, R. J., et al. (2012). WIKI4, a novel inhibitor of Tankyrase and Wnt/ß-Catenin signaling. PLoS ONE 7:e50457. doi: 10.1371/journal.pone.0050457
75. Janikowa, M., and Skarda, J. (2012). Differentiation pathways in carcinogenesis and in chemo- and radioresistance. Neoplasma 59, 6-17. doi: 10.4149/neo_2012_002
76. Jenison, R. D., Gill, S. C., Pardi, A., and Polisky, B. (1994). High-resolution molecular discrimination by RNA. Science 263, 1425-1429. doi: 10.1126/science.7510417
77. Jiang, F., Qiu, Q., Khanna, A., Todd, N. W., Deepak, J., Xing, L., et al. (2009). Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol. Cancer Res. 7, 330-338. doi: 10.1158/1541-7786.MCR-08-0393
78. Jiang, W., Peng, J., Zhang, Y., Cho, W. C., and Jin, K. (2012). The implications of cancer stem cells for cancer therapy. Int. J. Mol. Sci. 13, 16636-16657. doi: 10.3390/ijms131216636
79. Jin, L., Hope, J. K., Zhai, Q., Smadja-Joffe, F., and Dick, J. E. (2006). Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat. Med. 12, 1167-1174. doi: 10.1038/nm1483
80. Kennedy, B. J. (1970). Mithramycin therapy in advanced testicular neoplasms. Cancer 26, 755-766. doi: 10.1002/1097-0142(197010)26:4<755::AID-CNCR2820260403>3.0.CO;2-U
81. Ketola, K., Hilvo, M., Hyotylainen, T., Vuoristo, A., Ruskeepää, A. L., Orešic, M., et al. (2012). Salinomycin inhibits prostate cancer growth and migration via induction of oxidative stress. Br. J. Cancer 106, 19-106. doi: 10.1038/bjc.2011.530
82. Kim, Y., Wu, Q., Hamerlik, P., Hitomi, M., Sloan, A. E., Barnett, G. H., et al. (2013). Aptamer identification of brain tumor-initiating cells. Cancer Res. 73, 4923-4936. doi: 10.1158/0008-5472.CAN-12-4556
83. Kobune, M., Takimoto, R., Murase, K., Iyama, S., Sato, T., Kikuchi, S., et al. (2009). Drug resistance is dramatically restored by hedgehog inhibitors in CD34+ leukemic cells. Cancer Sci. 100, 948-955. doi: 10.1111/j.1349-7006.2009.01111.x
84. Kondo, T., Setoguchi, T., and Taga, T. (2004). Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc. Natl. Acad. Sci. U.S.A. 101, 781-786. doi: 10.1073/pnas.0307618100
85. Korkaya, H., Paulson, A., Charafe-Jauffret, E., Ginestier, C., Brown, M., Dutcher, J., et al. (2009). Regulation of mammary stem/progenitor cells by PTEN/Akt/ß-catenin signaling. PLoS Biol. 7:e1000121. doi: 10.1371/journal.pbio.1000121
86. Kunz, M., and Ibrahim, S. M. (2003). Molecular responses to hypoxia in tumor cells. Mol. Cancer 2:23. doi: 10.1186/1476-4598-2-23
87. Kwon, M. J., and Shin, Y. K. (2013). Regulation of ovarian cancer stem cells or tumor-initiating cells. Int. J. Mol. Sci. 14, 6624-6648. doi: 10.3390/ijms14046624
88. Landen, C. N. Jr., Goodman, B., Katre, A. A., Steg, A. D., Nick, A. M., Stone, R. L., et al. (2010). Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol. Cancer Ther. 9, 3186-3199. doi: 10.1158/1535-7163.MCT-10-0563
89. Lapidot, T., Sirard, C., Vormoor, J., Murdoch, B., Hoang, T., Caceres-Cortes, J., et al. (1994). A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367, 645-648. doi: 10.1038/367645a0
90. Lawson, D. A., Xin, L. I., Lukacs, R. U., Cheng, D., and Witte, O. N. (2007). Isolation and functional characterization of murine prostate stem cells. Proc. Natl. Acad. Sci. U.S.A. 104, 181-186. doi: 10.1073/pnas.0609684104
91. Lee, E., Salic, A., Kruger, R., Heinrich, R., and Kirschner, M. W. (2003). The roles of APC and Axin derived from experimental and theoretical analysis of the Wnt pathway. PLoS Biol. 1:E10. doi: 10.1371/journal.pbio.0000010
92. Lee, T. J., Jung, E. M., Lee, J. T., Kim, S., Park, J. W., Choi, K. S., et al. (2006). Mithramycin A sensitizes cancer cells to TRAIL-mediated apoptosis by down-regulation of XIAP gene promoter through Sp1 sites. Mol. Cancer Ther. 5, 2737-2746. doi: 10.1158/1535-7163.MCT-06-0426
93. Leizer, A. L., Alvero, A. B., Fu, H. H., Holmberg, J. C., Cheng, Y. C., Silasi, D. A., et al. (2011). Regulation of inflammation by the NF-kappa B pathway in ovarian cancer stem cells. Am. J. Reprod. Immunol. 65, 438-447. doi: 10.1111/j.1600-0897.2010.00914.x
94. Lewis, J. L. Jr. (1972). Chemotherapy of gestational choriocarcinoma. Cancer 30, 1517-1521. doi: 10.1002/1097-0142(197212)30:6<1517::AID-CNCR2820300616>3.0.CO;2-8
95. Li, C., Heidt, D. G., Dalerba, P., Burant, C. F., Zhang, L., Adsay, V., et al. (2007). Identification of pancreatic cancer stem cells. Cancer Res. 67, 1030-1037. doi: 10.1158/0008-5472.CAN-06-2030
96. Li, T., Su, Y., Mei, Y., Leng, Q., Leng, B., Liu, Z., et al. (2010). ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients' outcome. Lab. Invest. 90, 234-244. doi: 10.1038/labinvest.2009.127
97. Liu, C., Li, Y., Semenov, M., Han, C., Baeg, G. H., Tan, Y., et al. (2002). Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 108, 837-847. doi: 10.1016/S0092-8674(02)00685-2
98. Liu, M., Sakamaki, T., Casimiro, M. C., Willmarth, N. E., Quong, A. A., Ju, X., et al. (2010). The canonical NF-?B pathway governs mammary tumorigenesis in transgenic mice and tumor stem cell expansion. Cancer Res. 70, 10464-10473. doi: 10.1158/0008-5472.CAN-10-0732
99. Liu, P., Brown, S., Goktug, T., Channathodiyil, P., Kannappan, V., Hugnot, J. P., et al. (2012). Cytotoxic effect of disulfiram/copper on human glioblastoma cell lines and ALDH positive cancer-stem-like cells. Br. J. Cancer 9, 1488-1497. doi: 10.1038/bjc.2012.442
100. Liu, S., Dontu, G., Mantle, I. D., Patel, S., Ahn, N. S., Jackson, K. W., et al. (2006). Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res. 66, 6063-6071. doi: 10.1158/0008-5472.CAN-06-0054
101. Lorico, A., and Rappa, G. (2011). Phenotypic heterogeneity of breast cancer stem cells. J. Oncol. 2011:135039. doi: 10.1155/2011/135039
102. Lou, D., Wang, B., Wang, Y., and Cao, Y. (2012). Selective killing of cancer stem cells by a novel dual-targeting strategy. Med. Hypotheses 79, 430-432. doi: 10.1016/j.mehy.2012.06.012
103. Lupold, S. E., Hicke, B. J., Lin, Y., and Coffet, D. S. (2002). Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res. 62, 4029-4033.
104. Ma, S., Lee, T. K., Zheng, B. J., Chan, K. W., and Guan, X. Y. (2008). CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 27, 1749-1758. doi: 10.1038/sj.onc.1210811
105. MacDonald, B. T., Tamai, K., and He, X. (2009). Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev. Cell 17, 9-26. doi: 10.1016/j.devcel.2009.06.016
106. Majmundar, A. J., Wong, W. J., and Simon, M. C. (2010). Hypoxia-inducible factors and the response to hypoxic stress. Mol. Cell 40, 294-309. doi: 10.1016/j.molcel.2010.09.022
107. Marcu, L., and Olver, I. (2006). Tirapazamine: from bench to clinical trials. Curr. Clin. Pharmacol. 1, 71-79. doi: 10.2174/157488406775268192
108. McAuliffe, S. M., Morgan, S. L., Wyant, G. A., Tran, L. T., Muto, K. W., Chen, Y. S., et al. (2012). Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proc. Natl. Acad. Sci. U.S.A. 109, E2939-E2948. doi: 10.1073/pnas.1206400109
109. Meng, F., Evans, J. W., Bhupathi, D., Banica, M., Lan, L., Lorente, G., et al. (2012). Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302. Mol. Cancer Ther. 11, 740-751. doi: 10.1158/1535-7163.MCT-11-0634
110. Mezencev, R., Wang, L., and McDonald, J. F. (2012). Identification of inhibitors of ovarian cancer stem-like cells by high-throughput screening. J. Ovarian Res. 5, 30-41. doi: 10.1186/1757-2215-5-30
111. Mogi, M., Yang, J., Lambert, J. F., Colvin, G. A., Shiojima, I., Skurk, C., et al. (2003). Akt signaling regulates side population cell phenotype via Bcrp translocation. J. Biol. Chem. 278, 39068-39075. doi: 10.1074/jbc.M306362200
112. Moitra, K., Lou, H., and Dean, M. (2011). Multidrug efflux pumps and cancer stem cells: insights into multidrug resistance and therapeutic development. Clin. Pharmacol. Ther. 89, 491-502. doi: 10.1038/clpt.2011.14
113. Moreb, J. S. (2008). Aldehyde dehydrogenase as a marker for stem cells. Curr. Stem Cell Res. Ther. 3, 237-246. doi: 10.2174/157488808786734006
114. Naujokat, C. (2014). Monoclonal antibodies against human cancer stem cells. Immunotherapy 6, 290-308. doi: 10.2217/imt.14.4
115. Nesi, G., Colabufo, N. A., Contino, M., Perrone, M. G., Digiacomo, M., Perrone, R., et al. (2014). SAR study on Arylmethyloxyphenyl scaffold: looking for a P-gp nanomolar affinity. Eur. J. Med. Chem. 76, 558-566. doi: 10.1016/j.ejmech.2014.02.051
116. Oak, P. S., Kopp, F., Thakur, C., Ellwart, J. W., Rapp, U. R., Ullrich, A., et al. (2012). Combinatorial treatment of mammospheres with trastuzumab and salinomycin efficiently targets HER2-positve cancer cells and cancer stem cells. Int. J. Cancer 131, 2808-2019. doi: 10.1002/ijc.27595
117. Orfao, A., and Ruiz-Arguelles, A. (1996). General concepts about cell sorting techniques. Clin. Biochem. 29, 5-9. doi: 10.1016/0009-9120(95)02017-9
118. Park, J. T., Li, M., Nakayama, K., Mao, T. L., Davidson, B., Zhang, Z., et al. (2006). Notch3 gene amplification in ovarian cancer. Cancer Res. 66, 6312-6318. doi: 10.1158/0008-5472.CAN-05-3610
119. Patterson, L. H., Craven, M. R., Fisher, G. R., and Teesdale-Spittle P. (1994). Aliphatic amine N-oxides of DNA binding agents as bioreductive drugs. Oncol. Res. 6, 533-538.
120. Patterson, L. H., McKeown, S. R., Ruparelia, K., Double, J. A., Bibby, M. C., Cole, S., et al. (2000). Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent. Br. J. Cancer 82, 1984-1990. doi: 10.1054/bjoc.2000.1163
121. Perez-Tomas, R. (2006). Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr. Med. Chem. 13, 1859-1876. doi: 10.2174/092986706777585077
122. Perlia, C. P., Gubisch, N. J., Wolter, J., Edelberg, D., Dederick, M. M., and Taylor, S. G. 3rd. (1970). Mithramycin treatment of hypercalcemia. Cancer 25, 389-394. doi: 10.1002/1097-0142(197002)25:2<389::AID-CNCR2820250217>3.0.CO;2-X
123. Pharm, A. N., Penchala, S., Graf, R. A., Wang, J., and Huang, Y. (2008). "Pharmacogenomic characterization of ABC transporters involved in Multidrug Resistance," in Multidrug Resistance: Biological and Pharmaceutical Advance in the Antitumour Treatment, ed N. A. Colabufo (Kerala: Research Signpost), 19-62.
124. Phillips, R. M., Hendriks, H. R., and Peters, G. J. (2013). EO9 (Apaziquone): from the clinic to the laboratory and back again. Br. J. Pharmacol. 168, 11-18. doi: 10.1111/j.1476-5381.2012.01996.x
125. Pietras, A. (2011). Cancer stem cells in tumor heterogeneity. Adv. Cancer Res. 112, 255-281. doi: 10.1016/B978-0-12-387688-1.00009-0
126. Pollard, S. M., Yoshikawa, K., Clarke, I. D., Danovi, D., Stricker, S., Russell, R., et al. (2009). Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell 4, 568-580. doi: 10.1016/j.stem.2009.03.014
127. Proske, D., Blank, M., Buhmann, R., and Resch, A. (2005). Aptamers-basic research drug development and clinical applications. Appl. Microbiol. Biotechnol. 69, 367-374. doi: 10.1007/s00253-005-0193-5
128. Rauth, A. M., Melo, T., and Misra, V. (1998). Bioreductive therapies: an overview of drugs and their mechanisms of action. Int. J. Radiat. Oncol. Biol. Phys. 42, 755-762. doi: 10.1016/S0360-3016(98)00302-2
129. Riccioni, R., Dupuis, M. L., Bernabei, M., Petrucci, E., Pasquini, L., Mariani, G., et al. (2010). The cancer stem cell selective inhibitor salinomycin is a P-glycoprotein inhibitor. Blood Cells Mol. Dis. 45, 16-92. doi: 10.1016/j.bcmd.2010.03.008
130. Ricci-Vitiani, L., Lombardi, D. G., Pilozzi, E., Biffoni, M., Todaro, M., Peschle, C., et al. (2007). Identification and expansion of human colon-cancer-initiating cells. Nature 445, 111-115. doi: 10.1038/nature05384
131. Riobo, N. A., Lu, K., Ai, X., Haines, G. M., and Emerson, C. P. Jr. (2006). Phosphoinositide 3-kinase and AKT are essential for Sonic Hedgehog signaling. Proc. Natl. Acad. Sci. U.S.A. 103, 4505-4510. doi: 10.1073/pnas.0504337103
132. Rischin, D., Peters, L. J., O'Sullivan, B., Giralt, J., Fisher, R., Yuen, K., et al. (2010). Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J. Clin. Oncol. 28, 2989-2995. 10.1200/JCO.2009.27.4449
133. Sagiv, E., Starr, A., Rozovski, U., Khosravi, R., Altevogt, P., Wang, T., et al. (2008). Targeting CD24 for treatment of colorectal and pancreatic cancer by monoclonal antibodies or small interfering RNA. Cancer Res. 68, 2803-2812. doi: 10.1158/0008-5472.CAN-07-6463
134. Sasaki, H., Nishizaki, Y., Hui, C., Nakafuku, M., and Kondoh, H. (1999). Regulation of Gli2 and Gli3 activities by an amino-terminal repression domain: implication of Gli2 and Gli3 as primary mediators of Shh signaling. Development 126, 3915-3924.
135. Saunders, M. P., Jaffar, M., Patterson, A. V., Nolan, J., Naylor, M. A., Phillips, R. M., et al. (2000). The relative importance of NADPH: cytochrome c (P450) reductase for determining the sensitivity of human tumour cells to the indolequinone EO9 and related analogues lacking functionality at the C-2 and C-3 positions. Biochem. Pharmacol. 59, 993-996. doi: 10.1016/S0006-2952(99)00405-0
136. Sefah, K., Shangguan, D., Xiong, X. L., O'Donoghue, M. B., and Tan, W. (2010). Development of DNA aptamers using Cell-SELEX. Nat. Protoc. 5, 1169-1185. doi: 10.1038/nprot.2010.66
137. Shangguan, D., Li, Y., Tang, Z. W., Cao, Z. C., Chen, H. W., Mallikaratchy, P., et al. (2006). Aptamers evolved from live cells as effective molecular probes for cancer study. Proc. Natl. Acad. Sci. U.S.A. 103, 11838-11843. doi: 10.1073/pnas.0602615103
138. Shank, J. J., Yang, K., Ghannam, J., Cabrera, L., Johnston, C. J., Reynolds, R. K., et al. (2012). Metformin targets ovarian cancer stem cells in vitro and in vivo. Gynecol. Oncol. 127, 390-397. doi: 10.1016/j.ygyno.2012.07.115
139. Shinde, S. S., Maroz, A., Hay, M. P., Patterson, A. V., Denny, W. A., and Anderson, R. F. (2010). Characterization of radicals formed following enzymatic reduction of 3-substituted analogues of the hypoxia-selective cytotoxin 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine). J. Am. Chem. Soc. 132, 2591-2599. doi: 10.1021/ja908689f
140. Siemann, D. W., and Keng, P. C. (1986). Cell cycle specific toxicity of the Hoechst 33342 stain in untreated or irradiated murine tumor cells. Cancer Res. 46, 3556-3559.
141. Singh, S. K., Clarke, I. D., Terasaki, M., Bonn, V. E., Hawkins, C., Squire, J., et al. (2003). Identification of a cancer stem cell in human brain tumors. Cancer Res. 63, 5821-5828.
142. Singleton, R. S., Guise, C. P., Ferry, D. M., Pullen, S. M., Dorie, M. J., Brown, J. M., et al. (2009). DNA crosslinks in human tumor cells exposed to the prodrug PR-104A: relationships to hypoxia, bioreductive metabolism and cytotoxicity. Cancer Res. 69, 3884-3891. doi: 10.1158/0008-5472.CAN-08-4023
143. Smith, K. M., Datti, A., Fujitani, M., Grinshtein, N., Zhang, L., Morozova, O., et al. (2010). Selective targeting of neuroblastoma tumour-initiating cells by compounds identified in stem cell-based small molecule screens. EMBO Mol. Med. 2, 371-384. doi: 10.1002/emmm.201000093
144. Smith, L. M., Nesterova, A., Ryan, M. C., Duniho, S., Jonas, M., Anderson, M., et al. (2008). CD133/prominin-1 is a potential therapeutic target for antibodydrug conjugates in hepatocellular and gastric cancers. Br. J. Cancer 99, 100-109. doi: 10.1038/sj.bjc.6604437
145. Storms, R. W., Trujillo, A. P., Springer, J. B., Shah, L., Colvin, O. M., Ludeman, S. M., et al. (1999). Isolation of primitive human hematopoietic progenitors on the basis of aldehyde dehydrogenase activity. Proc. Natl. Acad. Sci. U.S.A. 96, 9118-9123. doi: 10.1073/pnas.96.16.9118
146. Stratford, E. W., Bostad, M., Castro, R., Skarpen, E., Berg, K., Høgset, A., et al. (2013). Photochemical internalization of CD133-targeting immunotoxins efficiently depletes sarcomacells with stem-like properties and reduces tumorigenicity. Biochim. Biophys. Acta 1830, 4235-4243. doi: 10.1016/j.bbagen.2013.04.033
147. Su, Y., Qiu, Q., Zhang, X., Jiang, Z., Leng, Q., Liu, Z., et al. (2010). Aldehyde dehydrogenase 1 A1-positive cell population is enriched in tumor-initiating cells and associated with progression of bladder cancer. Cancer Epidemiol. Biomarkers Prev. 19, 327-337. doi: 10.1158/1055-9965.EPI-09-0865
148. Takaishi, S., Okumura, T., Tu, S., Wang, S. S., Shibata, W., Vigneshwaran, R., et al. (2009). Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 27, 1006-1020. doi: 10.1002/stem.30
149. Takebe, N., Harris, P. J., Warren, R. Q., and Ivy, S. P. (2011). Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat. Rev. Clin. Oncol. 8, 97-106. doi: 10.1038/nrclinonc.2010.196
150. Tanaka, K., Okabayashi, K., Asashima, M., Perrimon, N., and Kadowaki, T. (2000). The evolutionarily conserved porcupine gene family is involved in the processing of the Wnt family. Eur. J. Biochem. 267, 4300-4311. doi: 10.1046/j.1432-1033.2000.01478.x
151. Tang, Q. L., Zhao, Z. Q., Li, J. C., Liang, Y., Yin, J. Q., Zou, C. Y., et al. (2011). Salinomycin inhibits osteosarcoma by targeting its tumor stem cells. Cancer Lett. 311, 113-121. doi: 10.1016/j.canlet.2011.07.016
152. Teng, Y., Wang, X., Wang, Y., and Ma, D. (2010). Wnt/ß-catenin signaling regulates cancer stem cells in lung cancer A549 cells. Biochem. Biophys. Res. Commun. 392, 373-379. doi: 10.1016/j.bbrc.2010.01.028
153. Teodori, E., Dei, S., Martelli, S., Scapecchi, F., and Gualtieri, F. (2006). The functions and structure of ABC transporters: implications for the design of new inhibitors of Pgp and MRP1 to control multidrug resistance (MDR). Curr. Drug Targets 7, 893-909. doi: 10.2174/138945006777709520
154. Thomas, T., Nowka, K., Lan, L., and Derwahl, M. (2006). Expression of endoderm stem cell markers: evidence for the presence of adult stem cells in human thyroid glands. Thyroid 16, 537-544. doi: 10.1089/thy.2006.16.537
155. Tomiyasu, S., Miyamoto, T., Mori, M., Yaguchi, T., Yakushiji, H., Ohno, S., et al. (2014). Isolation of side population cells from endometrial cancer cells using a violet laser diode. Hum. Cell 27, 36-42. doi: 10.1007/s13577-013-0079-2
156. Tuerk, C., and Gold, L. (1990). Systematic evolution of ligands by exponential enrichment-RNA ligands to bacteriophage-T4 DNA-polymerase. Science 249, 505-510. doi: 10.1126/science.2200121
157. Varjosalo, M., and Taipale, J. (2008). Hedgehog: functions and mechanisms. Genes Dev. 22, 2454-2472. doi: 10.1101/gad.1693608
158. Waaler, J., Machon, O., Tumova, L., Dinh, H., Korinek, V., Wilson, S. R., et al. (2012). A novel Tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice. Cancer Res. 72, 2822-2832. doi: 10.1158/0008-5472.CAN-11-3336
159. Waldron, N. N., Kaufman, D. S., Oh, S., Inde, Z., Hexum, M. K., Ohlfest, J. R., et al. (2011). Targeting tumor-initiating cancer cells with dCD133KDEL shows impressive tumor reductions in a xenotransplant model of human head and neck cancer. Mol. Cancer Ther. 10, 1829-1838. doi: 10.1158/1535-7163.MCT-11-0206
160. Wang, S., Huang, S., Zhao, X., Zhang, Q., Wu, M., Sun, F., et al. (2013a). Enrichment of prostate cancer stem cells from primary prostate cancer cultures of biopsy samples. Int. J. Clin. Exp. Pathol. 7, 184-193.
161. Wang, X., Moon, J., Dodge, M. E., Pan, X., Zhang, L., Hanson, J. M., et al. (2013b). The development of highly potent inhibitors for porcupine. J. Med. Chem. 56, 2700-2704. doi: 10.1021/jm400159c
162. Wang, Y. (2011). Effects of salinomycin on cancer stem cell in human lung adenocarcinoma A549 cells. Med. Chem. 7, 206-111. doi: 10.2174/157340611794859307
163. Wang, Z., Li, Y., Kong, D., Banerjee, S., Ahmad, A., Azmi, A. S., et al. (2009). Acquisition of epithelialmesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res. 69, 2400-2407. doi: 10.1158/0008-5472.CAN-08-4312
164. Whitworth, J. M., Londono-Joshi, A. I., Sellers, J. C., Oliver, P. J., Muccio, D. D., Atigadda, V. R., et al. (2012). The impact of novel retinoids in combination with platinum chemotherapy on ovarian cancer stem cells. Gynecol. Oncol. 125, 226-230. doi: 10.1016/j.ygyno.2011.12.425
165. Wintzell, M., Lofstedt, L., Johansson, J., Pedersen, A. B., Fuxe, J., and Shoshan, M. (2012). Repeated cisplatin treatment can lead to a multiresistant tumor cell population with stem cell features and sensitivity to 3-bromopyruvate. Cancer Biol. Ther. 13, 1454-1462. doi: 10.4161/cbt.22007
166. Wright, M. H., Calcagno, A. M., Salcido, C. D., Carlson, M. D., Ambudkar, S. V., and Varticovski, L. (2008). Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res. 10:R10. doi: 10.1186/bcr1855
167. Xia, J., Zhang, Y., Qian, J., Zhu, X., Zhang, Y., Zhang, J., et al. (2013). Isolation, identification and expression of specific human CD133 antibodies. Sci. Rep. 3:3320. doi: 10.1038/srep03320
168. Xin, L. I., Lawson, D. A., and Witte, O. N. (2005). The Sca-1 cell surface marker enriches for a prostate-regenerating cell subpopulation that can initiate prostate tumorigenesis. Proc. Natl. Acad. Sci. U.S.A. 102, 6942-6947. doi: 10.1073/pnas.0502320102
169. Yang, X., Zheng, X., Cao, J., Xiang, H., Liu, F., and Lv, Y. (2010). 8-bromo-7-methoxychrysin-induced apoptosis of hepatocellular carcinoma cells involves ROS and JNK. World J. Gastroenterol. 16, 27385-23393. doi: 10.3748/wjg.v16.i27.3385
170. Yasmeen, A., Beauchamp, M. C., Piura, E., Segal, E., Pollak, M., and Gotlieb, W. H. (2011). Induction of apoptosis by metformin in epithelial ovarian cancer: involvement of the Bcl-2 family proteins. Gynecol. Oncol. 121, 492-498. doi: 10.1016/j.ygyno.2011.02.021
171. Yeung, J., Esposito, M. T., Gandillet, A., Zeisig, B. B., Griessinger, E., Bonnet, D., et al. (2010). ß-catenin mediates the establishment and drug resistance of MLL leukemic stem cells. Cancer Cell 18, 606-618. doi: 10.1016/j.ccr.2010.10.032
172. Yin, J., Glaser, R., and Gates, K. S. (2012). On there action mechanism of tirapazamine reduction chemistry: unimolecular N-OH homolysis, stepwise dehydration, ortriazene ring-opening. Chem. Res. Toxicol. 25, 634-645. doi: 10.1021/tx200546u
173. Yo, Y. T., Lin, Y. W., Wang, Y. C., Balch, C., Huang, R. L., Chan, M. W., et al. (2012). Growth inhibition of ovarian tumor-initiating cells by niclosamide. Mol. Cancer Ther. 11, 1703-1712. doi: 10.1158/1535-7163.MCT-12-0002
174. Zeman, E. M., Brown, J. M., Lemmon, M. J., Hirst, V. K., and Lee, W. W. (1986). SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int. J. Radiat. Oncol. Biol. Phys. 12, 1239-1242. doi: 10.1016/0360-3016(86)90267-1
175. Zhang, S., Balch, C., Chan, M. W., Lai, H. C., Matei, D., Schilder, J. M., et al. (2008). Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 68, 4311-4320. doi: 10.1158/0008-5472.CAN-08-0364
176. Zhao, C., Chen, A., Jamieson, C. H., Fereshteh, M., Abrahamsson, A., Blum, J., et al. (2009). Hedgehog signaling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 458, 776-779. doi: 10.1038/nature07737
177. Zhi, Q. M., Chen, X. H., Ji, J., Zhang, J. N., Li, J. F., Cai, Q., et al. (2011). Salinomycin can effectively kill ALDH(high) stem-like cells on gastric cancer. Biomed. Pharmacother. 65, 509-515. doi: 10.1016/j.biopha.2011.06.006
178. Zhou, F., Mu, Y. D., Liang, J., Liu, Z. X., Chen, H. S., and Zhang, J. F. (2014). Expression and prognostic value of tumor stem cell markers ALDH1 and CD133 in colorectal carcinoma. Oncol. Lett. 7, 507-512. doi: 10.3892/ol.2013.1723
179. Zhou, J., Wulfkuhle, J., Zhang, H., Gu, P., Yang, Y., Deng, J., et al. (2007). Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc. Natl. Acad. Sci. U.S.A. 104, 16158-16163. doi: 10.1073/pnas.0702596104
180. Zhou, J., Zhang, H., Gu, P., Bai, J., Margolick, J. B., and Zhang, Y. (2008). NF-?B pathway inhibitors preferentially inhibit breast cancer stem-like cells. Breast Cancer Res. Treat. 111, 419-427. doi: 10.1007/s10549-007-9798-y